Skip to main content

Table 3 Treatment-related adverse events (n = 22)

From: A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer

n (%)All gradeGrade 3/4
Hematologic adverse events
 Leukopenia19 (86.4)6 (27.3)
 Neutropenia20 (90.9)7 (31.8)
 Anemia22 (100.0)1 (4.5)
 Thrombocytopenia5 (22.7)0 (0)
 Febrile neutropenia1 (4.5)1 (4.5)
Nonhematologic adverse events (≥ 10%)
 Nausea18 (81.8)0 (0)
 Vomiting4 (18.2)0 (0)
 Constipation19 (86.4)0 (0)
 Diarrhea5 (22.7)0 (0)
 Stomatitis5 (22.7)0 (0)
 Anorexia20 (90.9)1 (4.5)
 Fatigue15 (68.2)1 (4.5)
 Pain6 (27.3)0 (0)
 Fever3 (13.6)0 (0)
 Weight loss3 (13.6)0 (0)
 Alopecia15 (68.2)0 (0)
 Rash6 (27.3)0 (0)
 AST increase4 (18.2)0 (0)
 ALT increase9 (40.9)0 (0)
 ALP increase11 (50.0)0 (0)
 Blood bilirubin increase4 (18.2)0 (0)
 Creatinine increase7 (31.8)0 (0)
 Hypoalbuminemia18 (81.8)0 (0)
 Hyperkalemia15 (68.2)1 (4.5)
 Hypocalcemia4 (18.2)0 (0)
 Hypokalemia5 (22.7)0 (0)
 Hyponatremia5 (22.7)4 (18.2)
 Peripheral sensory neuropathy6 (27.3)1 (4.5)
 Myalgia3 (13.6)0 (0)
 Lung infection4 (18.2)4 (18.2)
  1. AST aspartate aminotransferase, ALT alanine aminotransferase